Peptide Schedule
FGL (FG Loop Peptide)15 residuesEVYVVAENQQGKSKAEach bubble = one amino acid. Size = residue mass. Color = chemical class.FGL (FG Loop Peptide)
Benefits
About FGL (FG Loop Peptide)
FGL is a synthetic pentadecapeptide corresponding to residues E681-A695 of the second fibronectin type III homology module of the neural cell adhesion molecule (NCAM). It was designed to mimic the specific region of NCAM that binds and activates fibroblast growth factor receptor 1 (FGFR1), making it a targeted FGFR1 agonist with potent neurotrophic and neuroprotective properties. Research on FGL spans over two decades and includes both preclinical and early clinical work. In rodent models of ischemic stroke, a single suboccipital injection of FGL given 24 hours before induced global ischemia significantly protected hippocampal CA1 neurons from death. The peptide also preserves metabolic function and presynaptic activity in hippocampal slice cultures exposed to oxygen-glucose deprivation, whether applied before or after the insult. FGL's cognitive benefits are among its most compelling features. Intracerebroventricular administration immediately after training in fear conditioning or water maze tasks produced long-lasting memory improvements persisting up to one month in rats. The peptide enhances long-term potentiation (LTP) in the dentate gyrus of freely moving animals, with effects lasting up to 24 hours — the first demonstration that mimicking the NCAM-FGFR interaction promotes hippocampal synaptic plasticity in vivo. Beyond neuroprotection and memory, FGL mobilizes endogenous neural stem cells from the subventricular zone and hippocampus after stroke, promoting remyelination and modulating neuroinflammation through microglial regulation. A Phase I clinical trial using intranasal FGL(L) at doses up to 200 mg in healthy volunteers confirmed tolerability with dose-proportional systemic exposure and detectable brain penetration.
Who Should Consider FGL (FG Loop Peptide)
- Individuals seeking cognitive enhancement and memory support
- Adults with age-related cognitive decline
- Researchers studying neuroprotection and neuroplasticity
- Post-stroke patients exploring recovery-adjunct peptides
- Individuals with traumatic brain injury in recovery phase
How FGL (FG Loop Peptide) Works
FGL acts as a direct agonist of fibroblast growth factor receptor 1 (FGFR1), binding to the receptor and inducing its phosphorylation in a manner that mimics the natural interaction between NCAM's second fibronectin type III module and FGFR1. Upon receptor activation, FGL triggers two primary intracellular signaling cascades: the Ras-MAPK pathway and the PI3K-Akt pathway. The MAPK arm drives neurite outgrowth, neuronal differentiation, and synaptic remodeling, while the PI3K-Akt arm promotes neuronal survival by suppressing pro-apoptotic signaling. At the synaptic level, FGL enhances presynaptic function through FGFR1-dependent mechanisms, increasing synaptophysin expression and accelerating neurotransmitter release. It also activates the PKC pathway, triggering activity-dependent delivery of AMPA receptors to postsynaptic membranes — a process that directly enhances synaptic strength and underlies its memory-consolidating effects. FGL also stimulates proliferation of endogenous neural stem cells in neurogenic niches, supporting post-injury regeneration.
What to Expect
Minimal noticeable effects. The peptide begins engaging FGFR1 signaling and initiating synaptic remodeling processes. Some users report subtle improvements in mental clarity.
Gradual improvements in focus, verbal recall, and working memory. Synaptic plasticity changes are building as AMPA receptor trafficking increases.
Peak cognitive benefits typically emerge. Noticeable improvements in memory consolidation, learning speed, and mental endurance.
Benefits often persist beyond the active dosing period due to structural synaptic changes and ongoing neurotrophic factor upregulation.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1mg | 5x/week |
| Moderate | 1.5mg | 5x/week |
| Aggressive | 2mg | 5x/week |
Note: FGL is a 15-amino-acid synthetic peptide derived from the second fibronectin type III module of the neural cell adhesion molecule (NCAM). The active clinical form is FGL(L), a dimerized version consisting of two FGL monomers linked together, which provides better blood-brain barrier penetration. A Phase I clinical trial has confirmed tolerability and safety of intranasal FGL(L) in healthy volunteers at doses up to 200 mg. Always source the dimerized FGL(L) form rather than the monomer for optimal CNS activity.
How to Inject FGL (FG Loop Peptide)
Reconstitute one vial of lyophilized FGL(L) with bacteriostatic water — use 2 mL per 5 mg vial. Gently swirl until fully dissolved; don't shake. Administer via subcutaneous injection into abdominal fat using an insulin syringe. Standard dose is 1-2 mg once daily, administered in the morning. Begin at 1 mg for the first 1-2 weeks before increasing. Follow a 5-days-on, 2-days-off schedule. Ensure you're using the dimerized FGL(L) form rather than the monomer for proper CNS bioavailability.
Cycling Protocol
Standard protocol is 5 days on, 2 days off for 6 weeks. Evaluate cognitive response before continuing. Some practitioners recommend 4 weeks off between cycles to maintain receptor sensitivity.
Pharmacokinetics
Source: Estimated 4-6 hours following subcutaneous administration; CSF concentrations stable up to 5 hours post-injection in rats (Anand et al., 2007)
Loading the interactive decay curve.
Side Effects
FGL has been well tolerated in both preclinical and early clinical studies. In the Phase I human trial using intranasal FGL(L) at doses of 25, 100, and 200 mg, adverse events were mild and transient. Two subjects at the 200 mg dose reported brief nasal burning lasting less than 3 minutes. No significant abnormalities were observed in ECG, vital signs, or laboratory parameters across any dose level. One preclinical concern worth noting: in a mouse kindling model of epilepsy, FGL treatment reduced the stimulation threshold for generalized seizures, raising questions about use in individuals with seizure disorders.
Contraindications
- Pregnancy and breastfeeding (insufficient human safety data)
- History of seizure disorders or epilepsy (preclinical data suggests possible lowered seizure threshold)
- Known hypersensitivity to FGL or NCAM-derived peptides
- Active brain tumors or CNS malignancies (FGFR1 activation may promote cell proliferation)
- Children under 18 (limited pediatric safety data in humans)
Drug Interactions
- FGFR inhibitors (e.g., erdafitinib, pemigatinib) may directly antagonize FGL effects
- Anticonvulsant medications — monitor closely given preclinical seizure threshold concerns
- Other neurotrophic peptides (Cerebrolysin, Dihexa) — potential additive effects; use caution with combination protocols
- No formal drug interaction studies have been conducted in humans
Storage & Stability
Molecular Profile
Related Peptides
References
- A synthetic neural cell adhesion molecule mimetic peptide promotes synaptogenesis and memory consolidationPubMed 15115815
- An NCAM-derived FGF-receptor agonist, the FGL-peptide, induces neurite outgrowth and neuronal survivalPubMed 15525346
- A synthetic NCAM-derived peptide, FGL, protects hippocampal neurons from ischemic insult in vitro and in vivoPubMed 16197499
- Tolerability, safety and pharmacokinetics of the FGLL peptide following intranasal administration in healthy volunteersPubMed 17375985
- The neural cell adhesion molecule-derived peptide FGL facilitates long-term plasticity in the dentate gyrus in vivoPubMed 21508096
- The NCAM-derived peptide FGL mobilizes endogenous neural stem cells and promotes regenerative capacity after strokePubMed 27352075